Supplements and Alogliptin.
Alogliptin, sold under the brand names Vipidia, Vipdomet, is a dipeptidyl peptidase-4 (DPP-4) inhibitor: it prolongs the action of incretin hormones.
Alogliptin is a DPP-4 inhibitor (dipeptidyl peptidase-4). Use is Type 2 diabetes as a second or third line oral agent. The class prolongs the action of endogenous incretin hormones (GLP-1 and GIP) by blocking their degradation, which raises insulin release in a way tied to glucose with low hypoglycaemia risk. UK prescribing centres on sitagliptin, linagliptin, alogliptin, and saxagliptin. The supplement surface is small because DPP-4 inhibitors have minimal CYP metabolism. Linagliptin is the cleanest in this respect. Clinical issues here are mostly glycaemic and additive. Berberine, cinnamon at extract doses, alpha lipoic acid, and chromium at high doses all carry small additive HbA1c effects. The stack rarely causes hypoglycaemia, but it is worth tracking in patients on tight glycaemic targets. Acute pancreatitis is a rare adverse effect flagged for the class.
We have not yet completed an explicit assessment of supplement interactions with Alogliptin in the Distil database. That is different from saying nothing exists. We surface this distinction deliberately: the Distil checker tells you when we have explicitly assessed a pair and when we have not, because both are useful information. If you take Alogliptin alongside a supplement, the checker below will surface anything already in our database, and the missing-item form at the bottom of the page routes uncatalogued pairs into our next curation pass.
What this list does not say. Pairs not flagged here are not implicitly safe. They are either not yet in our database, or fall outside our inclusion scope (food-supplement interactions only; for drug-drug interactions, the BNF is authoritative). Use the checker below to surface any supplement, and submit a missing item if you take something we have not catalogued.
How we grade severity, choose what's in scope, and what we exclude.
Every call on this page is reasoned. We publish the full rubric for severity tiers, the medication inclusion logic, the evidence grades we accept, and what we deliberately leave out. About three thousand words. Worth reading once if you use this tool more than occasionally.
Read the full methodologyWant this checked across everything you take?
This page checks the pairs you enter. The personalised Distil report goes further:
- the same graded, cited interaction check across your whole stack, not just the pairs you thought to type in
- where your current routine may be leaving you short of your goals
- the evidence-backed compounds worth adding, and the ones worth dropping
It's a paid report: £79, or £49 for the first 25 customers. The interactions check is one section of it, and you can read a real one in full before you buy.
See a real sample reportSomething missing?
If a supplement or medication you take isn't in our autocomplete, tell us. We go through what people flag every week and add what's missing.